---
title: "Black Diamond Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285538773.md"
datetime: "2026-05-07T11:19:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285538773.md)
  - [en](https://longbridge.com/en/news/285538773.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285538773.md)
---

# Black Diamond Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.16, beating the estimate of USD -0.1844.

EBIT: As of FY2026 Q1, the actual value is USD -12.28 M.

#### Cash Position

Black Diamond Therapeutics, Inc. reported cash, cash equivalents, and investments of $118.3 million as of March 31, 2026, a decrease from $128.7 million as of December 31, 2025. Net cash used in operations for the first quarter of 2026 was - $10.2 million, compared to net cash provided by operations of $53.4 million for the first quarter of 2025.

#### Operational Metrics

-   **License Revenue**: Black Diamond Therapeutics, Inc. reported no license revenue for the first quarter of 2026, compared to $70.0 million for the same period in 2025.
-   **Research and Development Expenses**: R&D expenses were $7.0 million for the first quarter of 2026, down from $10.5 million for the first quarter of 2025, primarily due to the progression of the Phase 2 clinical trial for silevertinib in NSCLC and the outlicensing of BDTX-4933.
-   **General and Administrative Expenses**: G&A expenses were $4.3 million for the first quarter of 2026, a decrease from $5.0 million for the same period in 2025, mainly due to continued operational efficiencies.
-   **Total Operating Expenses**: Total operating expenses were $11.259 million for the first quarter of 2026, compared to $15.470 million for the same period in 2025.
-   **Income (Loss) from Operations**: Black Diamond Therapeutics, Inc. reported an operating loss of - $11.259 million for the first quarter of 2026, contrasting with an operating income of $54.530 million for the same period in 2025.
-   **Interest Income**: Interest income increased to $1.023 million for the first quarter of 2026, up from $0.595 million in the first quarter of 2025.
-   **Other Income (Expense)**: Other income was $1.200 million for the first quarter of 2026, compared to $1.417 million for the same period in 2025.
-   **Net Loss**: Black Diamond Therapeutics, Inc. reported a net loss of - $9.0 million for the first quarter of 2026, significantly different from a net income of $56.5 million for the same period in 2025.

#### Balance Sheet Data (as of March 31, 2026)

-   **Total Assets**: $132.922 million.
-   **Accumulated Deficit**: - $473.776 million.
-   **Total Stockholders’ Equity**: $104.300 million.

#### Financial Guidance

Black Diamond Therapeutics, Inc. anticipates that its cash, cash equivalents, and investments totaling $118.3 million as of March 31, 2026, will be sufficient to fund its anticipated operating expenses and capital expenditure requirements. This funding is expected to last into the second half of 2028.

### Related Stocks

- [BDTX.US](https://longbridge.com/en/quote/BDTX.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)